Filing Flows › United Therapeutics (UTHR) › Net income
United Therapeutics (UTHR) net income by quarter
United Therapeutics' net income was $259M in Q3 2026 (third quarter 2026), -22% from Q2 2026. Over the last 7 quarters it ranged from $259M (Q3 2026) to $364M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $259M | -22% | -24% |
| Q2 2026 | $333M | +21% | +8% |
| Q1 2026 | $275M | -25% | -15% |
| Q4 2025 | $364M | +8% | — |
| Q3 2025 | $339M | +9% | — |
| Q2 2025 | $310M | -4% | — |
| Q1 2025 | $322M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' net income?
United Therapeutics' net income was $259M in Q3 2026 (third quarter 2026), -22% from Q2 2026.
How has United Therapeutics' net income changed?
Over the last 7 quarters it ranged from $259M (Q3 2026) to $364M (Q4 2025).